TD Cowen raised the firm’s price target on BrightSpring Health (BTSG) to $41 from $37 and keeps a Buy rating on the shares. The firm said the expected benefit from LDDs and generic conversions driving 2H adj. EBITDA growth are durable and are likely to benefit 2026 growth but it remains to be seen how 2H ultimately tracks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services: Strong Pharmacy Solutions Performance and Strategic Moves Justify Buy Rating
- BrightSpring Health Services Reports Strong Q2 2025 Results
- BrightSpring Health Services Reports Strong Earnings Growth
- BrightSpring Health reports Q2 cont. ops. EPS 4c, consensus 19c
- BrightSpring Health sees FY25 revenue $12.200B-$12.600B, consensus $12.34B